JP6575952B2 - イブルチニブ併用療法 - Google Patents

イブルチニブ併用療法 Download PDF

Info

Publication number
JP6575952B2
JP6575952B2 JP2016507617A JP2016507617A JP6575952B2 JP 6575952 B2 JP6575952 B2 JP 6575952B2 JP 2016507617 A JP2016507617 A JP 2016507617A JP 2016507617 A JP2016507617 A JP 2016507617A JP 6575952 B2 JP6575952 B2 JP 6575952B2
Authority
JP
Japan
Prior art keywords
ibrutinib
anticancer agent
lymphoma
cell
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016507617A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016521266A (ja
JP2016521266A5 (enExample
Inventor
ホール，ブレット
サッサー，エー．ケイト
シャファー，マイケル
デイビス，クック
カスネウフ，ティネケ
ヴェルセレ，マティアス
リグテンバーグ，ウィレム
チャン，ベティー
バラスブラマニアン，スリラム
クロウリー，リチャード
クオ，ス−ピン
Original Assignee
ファーマサイクリックス エルエルシー
ファーマサイクリックス エルエルシー
ジャンセン ファーマシューティカ エヌブイ
ジャンセン ファーマシューティカ エヌブイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファーマサイクリックス エルエルシー, ファーマサイクリックス エルエルシー, ジャンセン ファーマシューティカ エヌブイ, ジャンセン ファーマシューティカ エヌブイ filed Critical ファーマサイクリックス エルエルシー
Publication of JP2016521266A publication Critical patent/JP2016521266A/ja
Publication of JP2016521266A5 publication Critical patent/JP2016521266A5/ja
Application granted granted Critical
Publication of JP6575952B2 publication Critical patent/JP6575952B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2016507617A 2013-04-08 2014-04-08 イブルチニブ併用療法 Active JP6575952B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361809810P 2013-04-08 2013-04-08
US61/809,810 2013-04-08
PCT/US2014/033378 WO2014168975A1 (en) 2013-04-08 2014-04-08 Ibrutinib combination therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019147994A Division JP6871978B2 (ja) 2013-04-08 2019-08-09 イブルチニブ併用療法

Publications (3)

Publication Number Publication Date
JP2016521266A JP2016521266A (ja) 2016-07-21
JP2016521266A5 JP2016521266A5 (enExample) 2017-05-25
JP6575952B2 true JP6575952B2 (ja) 2019-09-18

Family

ID=51689963

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016507617A Active JP6575952B2 (ja) 2013-04-08 2014-04-08 イブルチニブ併用療法
JP2019147994A Active JP6871978B2 (ja) 2013-04-08 2019-08-09 イブルチニブ併用療法
JP2021069171A Pending JP2021119150A (ja) 2013-04-08 2021-04-15 イブルチニブ併用療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019147994A Active JP6871978B2 (ja) 2013-04-08 2019-08-09 イブルチニブ併用療法
JP2021069171A Pending JP2021119150A (ja) 2013-04-08 2021-04-15 イブルチニブ併用療法

Country Status (14)

Country Link
US (2) US20160287592A1 (enExample)
EP (1) EP2983670A4 (enExample)
JP (3) JP6575952B2 (enExample)
KR (1) KR20150141971A (enExample)
CN (2) CN111317821A (enExample)
AU (3) AU2014251028A1 (enExample)
BR (1) BR112015025711A8 (enExample)
CA (1) CA2908375A1 (enExample)
EA (1) EA201591656A1 (enExample)
HK (1) HK1215374A1 (enExample)
IL (2) IL241710B (enExample)
MX (2) MX369503B (enExample)
PH (2) PH12015502337A1 (enExample)
WO (1) WO2014168975A1 (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0906473A8 (pt) 2008-01-04 2016-02-10 Intellikine Inc Certas entidades químicas, composições e métodos
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CN102159214A (zh) 2008-07-16 2011-08-17 药品循环公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
MX380504B (es) 2010-06-03 2025-03-12 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
EP3238722B1 (en) 2011-01-10 2019-03-13 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones
KR20140048968A (ko) 2011-07-13 2014-04-24 파마시클릭스, 인코포레이티드 브루톤형 티로신 키나제의 억제제
CN103889987B (zh) 2011-07-19 2016-09-14 默沙东有限责任公司 作为btk抑制剂的选择的咪唑并吡嗪类
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
DK2734205T3 (en) 2011-07-21 2018-06-14 Tolero Pharmaceuticals Inc Heterocyclic Protein Kinase Inhibitors
MA37711A1 (fr) 2012-06-04 2017-05-31 Pharmacyclics Inc Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
HK1206073A1 (en) 2012-07-24 2015-12-31 药品循环有限责任公司 Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
PT2970205T (pt) 2013-03-14 2019-08-26 Tolero Pharmaceuticals Inc Inibidores da jak2 e da alk2 e métodos para a sua utilização
JP6430483B2 (ja) 2013-03-15 2018-11-28 ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 化学療法の間の正常細胞の一時的な保護
CA2906157C (en) 2013-03-15 2022-05-17 G1 Therapeutics, Inc. Highly active anti-neoplastic and anti-proliferative agents
JP6800750B2 (ja) * 2013-08-02 2020-12-16 ファーマサイクリックス エルエルシー 固形腫瘍の処置方法
CA2920534A1 (en) 2013-08-12 2015-02-19 Pharmacyclics Llc Methods for the treatment of her2 amplified cancer
CA3103411A1 (en) * 2013-10-25 2015-04-30 Pharmacyclics Llc Use of ibrutinib for treating and preventing chronic graft versus host disease
EP3076974A1 (en) 2013-12-05 2016-10-12 Acerta Pharma B.V. Therapeutic combination of a pi3k inhibitor and a btk inhibitor
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
WO2015146159A1 (en) 2014-03-25 2015-10-01 Ono Pharmaceutical Co., Ltd. Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma
US9937171B2 (en) 2014-04-11 2018-04-10 Acerta Pharma B.V. Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015161283A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
WO2015193740A2 (en) * 2014-06-17 2015-12-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor
SMT202100674T1 (it) 2014-08-11 2022-01-10 Acerta Pharma Bv Combinazioni terapeutiche di un inibitore di btk e un inibitore di bcl-2
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
TW201628622A (zh) * 2014-11-17 2016-08-16 製藥公司 Tlr抑制劑與布魯頓氏(bruton's)酪胺酸激酶抑制劑之組合
WO2016090255A1 (en) * 2014-12-05 2016-06-09 Sriram Balasubramanian Biological markers for predicting responsiveness to ibrutinib and r-chop combination therapy and methods of using the same
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
US9717745B2 (en) * 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
MA41827A (fr) * 2015-03-27 2018-01-30 Pharmacyclics Llc Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
KR20170134462A (ko) 2015-04-13 2017-12-06 다이이찌 산쿄 가부시키가이샤 Mdm2 저해제와 btk 저해제의 병용 치료법
MX391720B (es) 2015-04-20 2025-03-21 Epizyme Inc Terapia combinada para tratar cáncer.
IL293821A (en) 2015-07-02 2022-08-01 Acerta Pharma Bv Solid forms and formulations of (S)-4-(8-amino-3-(1-(but-2-aminoyl)pyrrolidine-2-yl)imidazo[5,1-yl]pyrazin-1-yl)-en- (pyridine-2-yl)benzamide
JP2018522028A (ja) * 2015-07-31 2018-08-09 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤の組み合わせ及びそれらの使用
AU2016304172A1 (en) * 2015-08-03 2018-03-15 Gilead Sciences, Inc. Combination therapies for treating cancers
EP3355871A1 (en) * 2015-10-02 2018-08-08 Gilead Sciences, Inc. Combinations of the btk inhibitor gs-4059 with inhibitors selected from a jak, ask1, brd and/or mmp9 inhibitor to treat cancer, allergic disorders, autoimmune diseases or inflammatory diseases
WO2017087947A2 (en) * 2015-11-19 2017-05-26 Pharmacyclics Llc Method of treatment of follicular lymphoma with a btk inhibitor
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
AU2017290362B2 (en) 2016-07-01 2021-08-05 Pharmacosmos Holding A/S Synthesis of N-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines
EP3484477B1 (en) 2016-07-14 2023-09-13 Mingsight Pharmaceuticals, Inc. Treatment of cancer
KR101911063B1 (ko) * 2016-07-29 2018-10-23 이화여자대학교 산학협력단 크로메논 유도체 및 이를 포함하는 항암용 조성물
CN109789127B (zh) 2016-07-29 2022-03-25 英克特诺治疗公司 吲哚啉酮化合物的用途
IL317919A (en) 2016-12-05 2025-02-01 G1 Therapeutics Inc Preservation of immune response during chemotherapy regimens
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
EP3626239B1 (en) * 2017-05-18 2024-07-03 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Ezh2 inhibitor combined with btk inhibitor for treating tumor
CN111565721A (zh) * 2017-09-19 2020-08-21 西普拉有限公司 具有增强的生物利用度的包含依鲁替尼和生物碱的组合物
TW201922256A (zh) 2017-10-27 2019-06-16 中國大陸商浙江導明醫藥科技有限公司 治療淋巴樣惡性疾病之方法
CN112165939A (zh) * 2018-03-21 2021-01-01 梅制药公司 联合疗法
BR112020020246A8 (pt) 2018-04-05 2022-10-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de cinase axl e uso dos mesmos
MX2020010556A (es) 2018-04-13 2021-03-02 Sumitomo Pharma Oncology Inc Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer.
BR112020022185A2 (pt) 2018-05-03 2021-02-02 Juno Therapeutics Inc terapia de combinação de uma terapia de células t do receptor de antígeno quimérico (car) e um inibidor de quinase
KR20210038906A (ko) 2018-07-26 2021-04-08 스미토모 다이니폰 파마 온콜로지, 인크. 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
CA3095699A1 (en) * 2018-07-31 2020-02-06 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
KR102962306B1 (ko) 2018-08-24 2026-05-08 쥐원 쎄라퓨틱스, 인크. 1,4-디아자스피로[5.5]운데칸-3-온의 개선된 합성
JP7541974B2 (ja) * 2018-08-26 2024-08-29 カーディフ・オンコロジー・インコーポレイテッド Ｐｌｋ１標的のリン酸化状態及びｐｌｋ１阻害剤を用いた癌の治療
US20220362357A1 (en) * 2018-08-31 2022-11-17 Stichting Radboud Universitair Medisch Centrum Synergistic Combinations of Amino Acid Depletion Agent Sensitizers (AADAS) and Amino Acid Depletion Agents (AADA), and Therapeutic Methods of Use Thereof
JP2022500408A (ja) * 2018-09-12 2022-01-04 デノボ バイオファーマ エルエルシー エンザスタウリンとｂｔｋの阻害剤との組合せおよびその使用
US20200171001A1 (en) * 2018-11-30 2020-06-04 Aptose Biosciences Inc. Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations
JP2022513666A (ja) * 2018-11-30 2022-02-09 ヤンセン バイオテツク，インコーポレーテツド 濾胞性リンパ腫の治療方法
HUE072069T2 (hu) 2019-02-12 2025-10-28 Sumitomo Pharma America Inc 2-((1R,4R)-4-((3-(3-(trifluormetil)fenil)imidazo[1,2- b]piridazin-6-il)amino)ciklohexil)propán-2-ol sósavas sójának kristályos formája
US20200262925A1 (en) * 2019-02-15 2020-08-20 Janssen Biotech, Inc. Combination Therapy For Treatment Of B-Cell Malignancies
WO2020186149A1 (en) * 2019-03-13 2020-09-17 The Brigham And Women's Hospital, Inc. Targeting regulatory b cells and their regulators for cancer immunotherapy
EP4101468A4 (en) * 2020-02-05 2024-02-28 Carna Biosciences, Inc. Anticancer agent composition
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
GB202009764D0 (en) * 2020-06-26 2020-08-12 Cambridge Entpr Ltd Therapeutic treatment using protein kinase c (pkc) inhibitors and cytotoxic agents
US20230010803A1 (en) * 2021-06-30 2023-01-12 Janssen Pharmaceutica Nv Treatments for diffuse large b-cell lymphoma
WO2023285677A1 (en) * 2021-07-16 2023-01-19 Spexis Ag Pharmaceutical combinations for treating cancer
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
CN115554301A (zh) * 2022-10-24 2023-01-03 徐诺药业(南京)有限公司 Hdac抑制剂和伊布替尼在制备预防或者治疗套细胞淋巴瘤的药物中的用途
AU2023372386A1 (en) 2022-10-31 2025-05-08 Sumitomo Pharma America, Inc. Pim1 inhibitor for treating myeloproliferative neoplasms
WO2025249980A1 (ko) * 2024-05-31 2025-12-04 (주)노보메디슨 림프종의 예방 또는 치료를 위한 포셀티닙의 병용투여 요법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008001156A1 (en) * 2006-06-26 2008-01-03 Centre Regional De Lutte Contre Le Cancer - Centre Francois Baclesse CANCER THERAPY USING BcI-XL-SPECIFIC siNA
EP2529621B1 (en) * 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
EP2126082A1 (en) * 2007-03-02 2009-12-02 MDRNA, Inc. Nucleic acid compounds for inhibiting bcl2 gene expression and uses thereof
DK2134374T3 (en) * 2007-03-14 2014-02-24 Bionsil S R L In Liquidazione BTK-INHIBITORS FOR USE IN PROCESSING chemotherapeutic agent RESISTANT TUMORS Epithelial
WO2009118384A1 (en) * 2008-03-27 2009-10-01 Janssen Pharmaceutica Nv Quinazolinone derivatives as tubulin polymerization inhibitors
ES2546294T7 (es) * 2009-05-26 2024-06-06 Abbvie Ireland Unlimited Co Agentes inductores de la apoptosis para el tratamiento de cáncer y enfermedades inmunitarias y autoinmunitarias
MX380504B (es) * 2010-06-03 2025-03-12 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
EP3919079A1 (en) * 2012-09-07 2021-12-08 Genentech, Inc. Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor

Also Published As

Publication number Publication date
BR112015025711A8 (pt) 2019-12-17
AU2019203205A1 (en) 2019-05-30
MX2019013429A (es) 2020-09-21
CN111317821A (zh) 2020-06-23
IL263026A (en) 2018-12-31
JP2016521266A (ja) 2016-07-21
MX369503B (es) 2019-11-11
EP2983670A4 (en) 2017-03-08
EA201591656A1 (ru) 2016-05-31
IL241710B (en) 2018-11-29
KR20150141971A (ko) 2015-12-21
WO2014168975A1 (en) 2014-10-16
CN105263496A (zh) 2016-01-20
EP2983670A1 (en) 2016-02-17
JP2021119150A (ja) 2021-08-12
PH12020552065A1 (en) 2021-05-10
MX2015013970A (es) 2016-07-08
PH12015502337A1 (en) 2016-02-22
CA2908375A1 (en) 2014-10-16
HK1215374A1 (zh) 2016-08-26
AU2021200066A1 (en) 2021-03-18
JP6871978B2 (ja) 2021-05-19
BR112015025711A2 (pt) 2017-07-18
JP2020002146A (ja) 2020-01-09
AU2014251028A1 (en) 2015-11-05
US20200368235A1 (en) 2020-11-26
US20160287592A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
JP6871978B2 (ja) イブルチニブ併用療法
JP7054681B2 (ja) 組合せ療法
CN106659716B (zh) 阿吡莫德组合物及其使用方法
IL277239A (en) MDM2 inhibitors and their combinations
CN103764144B (zh) Pi3k抑制剂与mek抑制剂的协同组合
JP2021121611A (ja) アピリモドを用いる癌の処置方法
RU2739992C2 (ru) Композиции апилимода и способы их применения в лечении колоректального рака
TW201628622A (zh) Tlr抑制劑與布魯頓氏(bruton's)酪胺酸激酶抑制劑之組合
US20160129003A1 (en) Pharmaceutical Combinations
JP6147246B2 (ja) Ａｋｔ及びｍｅｋ阻害剤化合物の組み合わせ、及び使用方法
JP2020512977A (ja) Ｃｈｋ１阻害剤とｗｅｅ１阻害剤との組み合わせ
US20120308562A1 (en) Methods of treating mesothelioma with a pi3k inhibitor compound
TW202131917A (zh) 併用醫藥
CN113329749A (zh) 用于治疗葡萄膜黑色素瘤的联合疗法
WO2013059548A1 (en) Compositions and methods for treating cancer using jak2 inhibitor
EP3880207B1 (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
US7888341B2 (en) Combination of glivec (STI571) with a cyclin-dependent kinase inhibitor, especially flavopiridol, in the treatment of cancer
HK40032432A (en) Ibrutinib combination therapy
WO2023011415A1 (zh) Egfr抑制剂的药物组合及其应用
JP2023549272A (ja) 癌を治療するためのトランス－［テトラクロリドビス（１ｈ－インダゾール）ルテニウム酸ナトリウム（ｉｉｉ）］の使用
HK40106272A (en) Egfr inhibitor and perk activator in combination therapy and their use for treating cancer
NZ786604A (en) Combination therapy with notch and cdk4/6 inhibitors for the treatment of

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170407

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170407

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180503

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190502

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190716

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190814

R150 Certificate of patent or registration of utility model

Ref document number: 6575952

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250